G. BouSamra, M.D. v. Excela Health, Aplts. ( 2019 )


Menu:
  •                             [J-80-2018] [MO: Mundy, J.]
    IN THE SUPREME COURT OF PENNSYLVANIA
    WESTERN DISTRICT
    GEORGE R. BOUSAMRA, M.D.                        :    No. 5 WAP 2018
    :
    :    Appeal from the Order of the Superior
    v.                                :    Court entered July 19, 2017 at No.
    :    1637 WDA 2015, affirming the Order
    :    of the Court of Common Pleas of
    EXCELA HEALTH, A CORPORATION;                   :    Allegheny County entered October 6,
    WESTMORELAND REGIONAL                           :    2015 at No. G.D. 12-003929, and
    HOSPITAL, DOING BUSINESS AS                     :    remanding
    EXCELA WESTMORELAND HOSPITAL,                   :
    A CORPORATION; ROBERT ROGALSKI;                 :    ARGUED: October 24, 2018
    JEROME E. GRANATO, M.D.; LATROBE                :
    CARDIOLOGY ASSOCIATES, INC., A                  :
    CORPORATION; ROBERT N. STAFFEN,                 :
    M.D.; MERCER HEALTH & BENEFITS,                 :
    LLC; AND AMERICAN MEDICAL                       :
    FOUNDATION FOR PEER REVIEW AND                  :
    EDUCATION, INC., A CORPORATION                  :
    :
    :
    APPEAL OF: EXCELA HEALTH,                       :
    WESTMORELAND REGIONAL                           :
    HOSPITAL, ROBERT ROGALSKI,                      :
    JEROME E. GRANATO, M.D., AND                    :
    LATROBE CARDIOLOGY ASSOCIATES,                  :
    INC.                                            :
    CONCURRING OPINION
    JUSTICE DONOHUE                                      DECIDED: JUNE 18 2019
    I join in the Majority’s determination that Excela Health (“Excela”) waived attorney-
    client privilege when its in-house counsel (Timothy Fedele (“Fedele”)) disseminated
    confidential communications prepared by an outside attorney to a third party, Molly Cate
    (“Cate”), a principal of a public relations consulting firm (Jarrard, Phillips, Cate & Hancock
    (“Jarrard”)). I also concur in the Majority’s decision to adopt a test for waiver of the work
    product privilege akin to that set forth in section 91(4) of the Restatement (Third) of the
    Law Governing Lawyers (“Restatement”). I write separately, however, to offer what I
    consider to be a significant, if not dispositive, consideration for the trial court when
    applying the test adopted here on remand.
    With respect to the attorney-client privilege, the Majority correctly indicates that the
    general rule is that this privilege is waived when the confidential communication at issue
    is shared with a third party. Majority Op. at 23. The Majority recognizes that Jarrard was
    a third party, as Cate was not an employee, officer, executive or director of Excela. 
    Id. at 28.
    Moreover, no exception to the general rule applied here, as Fedele’s transmittal of
    the confidential communication was not for the purpose of assisting outside counsel in
    providing legal advice to Excela. 
    Id. Fedele did
    not request input, advice or an opinion
    on outside counsel’s work from Jarrard. 
    Id. As a
    result, Fedele’s sharing of outside
    counsel’s communications with Cate resulted in a clear waiver of the attorney-client
    privilege.
    Turning to the issue of waiver of the work product doctrine,1 the starting point must
    be this Court’s recognition in Lepley v. Lycoming County Court of Common Pleas, 393
    1  The Majority indicates that the purpose of the work product doctrine is to “protect the
    mental impressions and processes of an attorney acting on behalf of a client, regardless
    of whether the work product was prepared in anticipation of litigation.” Majority Op. at 14.
    I take issue with this statement of the law in two respects. First, it is dicta, as our grant of
    allocatur with respect to the work product doctrine was limited to the issue of its waiver,
    not its scope. BouSamra. v. Excela Health, 
    179 A.3d 1079
    (Pa. 2018) (per curiam).
    Contrary to the Majority’s contention, it is unnecessary to define the scope of the work
    product doctrine in order to delineate a waiver test for whatever materials are deemed to
    be immune from discovery pursuant to said doctrine. The present case provides a clear
    example of this point, as we have identified a waiver test without any consideration of
    [J-80-2018] [MO: Mundy, J.] - 2
    whether the materials in question constitute, or do not constitute, attorney work product.
    To the contrary, our grant of allocatur presumed that the documents at issue were
    otherwise (i.e., absent waiver) protected by the work product doctrine. In its Opinion the
    Majority makes the same presumption, as it merely announces that the documents are
    attorney work product without any disclosure of the nature or contents of those documents
    (including whether or not they were prepared in anticipation of litigation). See Majority
    Op. at 17 n.8. As such, the Majority’s contention that we should not “declare the work
    product protection waived without first determining its applicability to the facts,” 
    id. at 13
    n.5, is simply untrue, as there are no “facts” in this case upon which to do so. In sum, the
    Majority’s discussion of the scope of the doctrine sheds no light on the issue of waiver of
    the doctrine’s protections.
    Second, the Majority expands the work product doctrine’s protections outside of
    the litigation context, such that any “mental impressions and processes of an attorney
    acting on behalf of a client,” are protected without regard to whether counsel’s actions
    were undertaken in anticipation of (or in connection with) litigation. Majority Op. at 14.
    While this Court has never issued a definitive statement regarding the scope of the
    attorney work product doctrine, on those occasions when we have commented on its
    breadth, this Court has consistently reflected that it applies in connection with efforts to
    defend clients against adversaries in litigation. See, e.g., Commonwealth v. Kennedy,
    
    876 A.3d 939
    , 948 (Pa. 2005) (emphasis added) (indicating that the work product doctrine
    “promotes the adversary system by enabling attorneys to prepare cases without fear that
    their work product will be used against their clients”) (quoting Westinghouse Electric
    Corporation v. Republic of the Philippines, 
    951 F.2d 1414
    , 1428 (3d Cir. 1991)); Lepley
    v. Lycoming County Court of Common Pleas, 
    393 A.2d 306
    , 310 (Pa. 1978) (“At its core,
    the work-product doctrine shelters the mental impressions of the attorney, providing a
    privileged area within which he can analyze and prepare his client’s case.”) (emphasis
    added) (quoting United States v. Nobles, 
    422 U.S. 225
    , 238 (1975)). Similarly, we have
    indicated that the doctrine protects “the confidentiality of papers prepared by or on behalf
    of attorneys in anticipation of litigation.” Commonwealth v. Williams, 
    86 A.3d 771
    , 59
    n.16 (Pa. 2014) (quoting 
    Westinghouse, 951 F.2d at 1428
    ).
    In expanding the scope of the attorney work product doctrine well beyond the
    bounds recognized by this Court to date, the Majority relies exclusively upon two cases
    from our intermediate appellate courts to conclude that the “in anticipation of litigation”
    language in Rule 4003.3 is inclusive rather than exclusive. Majority Op. at 14 n.6 (citing
    In re Estate of Paterno v. NCAA, 
    168 A.3d 187
    (Pa. Super. 2017) and Bagwell v. Pa.
    Dept. of Educ., 
    103 A.3d 409
    (Pa. Commw. 2014)). As explained herein, there is good
    reason to question the correctness of these decisions, and without advocacy and a careful
    and detailed analysis by this Court, I am unwilling to unreflexively adopt their conclusions
    in dicta here. These two cases rely upon a questionable distinction between federal and
    Pennsylvania procedural rules, a difference that this Court has not recognized. In
    Paterno, for example, the court noted that while Rule 26(b)(3)(A) of the Federal Rules of
    Civil Procedure states that a party may not discover documents and tangible things
    “prepared in anticipation of litigation,” Pennsylvania’s Rule 4003.3 “does not similarly
    [J-80-2018] [MO: Mundy, J.] - 
    3 A.2d 306
    (Pa. 1978) that work product is “not protected against compelled disclosure by
    a Constitutional, statutory, or common-law privilege[.]” 
    Id. at 310.
    Instead, protection for
    an attorney’s work product is set forth in Rule 4003.3 of our procedural rules as adopted
    by this Court:
    Subject to the provisions of Rules 4003.4 and 4003.5, a party
    may obtain discovery of any matter discoverable under Rule
    4003.1 even though prepared in anticipation of litigation or
    trial by or for another party or by or for that other party's
    representative, including his or her attorney, consultant,
    surety, indemnitor, insurer or agent. The discovery shall not
    include disclosure of the mental impressions of a party's
    attorney or his or her conclusions, opinions, memoranda,
    notes or summaries, legal research or legal theories. With
    respect to the representative of a party other than the party's
    attorney, discovery shall not include disclosure of his or her
    mental impressions, conclusions or opinions respecting the
    value or merit of a claim or defense or respecting strategy or
    tactics.
    Pa.R.C.P. 4003.3 (emphasis added).
    On its face, the highlighted portion of the rule suggests that an attorney’s work
    product may never be subject to discovery during litigation, as it does not appear to admit
    to any exceptions. In practice, however, this is not the case. The explanatory comment
    provides one such exception, specifically the circumstance in which the legal opinion of
    an attorney becomes a relevant issue in the litigation, including for example in an action
    cabin Pennsylvania’s work product privilege.” 
    Paterno, 168 A.3d at 200
    . When this Court
    adopted Rule 4003.3 in 1978, however, we did not recognize any intent to differentiate
    our rule from its federal counterpart in this manner. To the contrary, the explanatory
    comment recognizes just two distinctions from its federal counterpart: the federal rule
    permits discovery of work product only upon a showing of substantial need, and our rule
    distinguishes between the protections afforded to the attorney and to a party’
    representative. Pa.R.C.P. 4003.3 Explanatory Comment – 1978. Accordingly, the
    explanatory note does not acknowledge the distinction from federal law that the Superior
    Court attempted to draw in Paterno.
    [J-80-2018] [MO: Mundy, J.] - 4
    for malicious prosecution or abuse of process in which the defense is based upon a good
    faith reliance on the advice of counsel.       Pa.R.C.P. 4003.3 Explanatory Comment.
    Moreover, Excela freely admits that the work product protection may be waived if it is
    given “to a newspaper, putting it on a website, or otherwise widely disseminating [it.]”
    Excela’s Reply Brief at 10.
    In determining when work product protections have been waived, I agree with the
    Majority’s adoption of a test aligned with the one set forth in section 91 of the
    Restatement.2 This provision states, in relevant part, that “[w]ork-product immunity is
    waived if the client, the client’s lawyer, or another authorized agent of the client …
    discloses the material to third persons in circumstances in which there is a significant
    likelihood that an adversary or potential adversary in anticipated litigation will obtain it.”
    Restatement § 91(4) (2000). As the Majority appropriately notes, this test has been widely
    adopted and applied by federal and state courts alike. See, e.g., In re Chevron Corp.,
    
    633 F.3d 153
    , 165 (3d Cir. 2011); United States v. Massachusetts Institute of Technology
    (MIT), 
    129 F.3d 681
    , 687 (1st Cir. 1997); Continental Cas. Co. v. Under Armour, Inc., 
    537 F. Supp. 2d 761
    , 772 (D. Md. 2008); Kittitas Cty. v. Allphin, 
    416 P.3d 1232
    , 1243 (Wash.
    App. 2018), as amended (June 18, 2018); O'Boyle v. Borough of Longport, 
    94 A.3d 299
    ,
    2 Subsection (2) of section 87 further defines “work product” as consisting of two distinct
    types, “opinion work product” and “ordinary work product.”
    (2) Opinion work product consists of the opinions or mental impressions of
    a lawyer; all other work product is ordinary work product.
    Restatement § 87(2) (2000). The present case clearly involved opinion work product.
    Subsection 91 of the Restatement, however, does not distinguish between these two
    types of work product when discussing possible waivers of work product immunity.
    [J-80-2018] [MO: Mundy, J.] - 5
    313 (N.J. 2014); Am. Zurich Ins. Co. v. Mont. Thirteenth Judicial Dist. Court, 
    280 P.3d 240
    , 248 (Mont. 2012).
    This test is appropriate under Pennsylvania law. Waiver of work product immunity
    should appropriately be limited in accordance with the purpose of its protections, which
    this Court described in the explanatory comment to Rule 4003.3 to be “to keep the files
    of counsel free from examination by the opponent[.]” Pa.R.C.P. 4003.3 Explanatory
    Comment – 1978.          Whereas the attorney-client privilege is designed to protect
    confidentiality, the work product doctrine works to protect against disclosure to
    adversaries. 
    Id. Section 91
    of the Restatement appropriately limits instances of waiver
    in accordance with the essential purpose for providing the doctrine’s protections – to keep
    the work product from adversaries in litigation.
    For purposes of remand to the trial court, one refinement to the test for waiver of
    work product adopted here is in order. As described by the Majority, the test requires an
    analysis of whether the work product is “disclosed in a manner which significantly
    increases the likelihood that an adversary or potential adversary will obtain it.” Majority
    Op. at 16 (emphasis added).        As such, the manner of disclosure is an important
    consideration in applying the test, as disclosure must be effectuated by taking adequate
    precautions to ensure that the information cannot find its way into the hands of an
    adversary.   As one federal court has keenly observed, “failure to take adequate
    precautions to prevent an adversary from obtaining work product information warrants
    waiver because ‘[i]ndifference to such a consequence indicates that protection of the
    immunity was not important to the person claiming the protection.’” Continental, 537 F.
    Supp. 2d at 772 (quoting Restatement § 91 comment b); see also Chevron, 633 F.3d at
    [J-80-2018] [MO: Mundy, J.] - 6
    165 (waiver occurs only when “the material is disclosed in a manner inconsistent with
    keeping it from an adversary”); 
    MIT, 129 F.3d at 687
    (“disclosing material in a way
    inconsistent with keeping it from an adversary waives work product material”); 
    O’Boyle, 94 A.3d at 313
    ) (“The inquiry invariably devolves to an examination of the nature of the
    disclosure itself.”).
    As a result, in applying the waiver test, the trial court will need to focus on whether
    Fedele, when disseminating outside counsel’s work product to Cate, took any or all of the
    necessary and available precautions to reduce or eliminate the likelihood that the
    information could be obtained by Appellant, Dr. BouSamra.3 The manner in which Fedele
    3  Respectfully, the emphasis on Fedele’s actions does not, as the Majority contends,
    focus too heavily on the confidentiality of the documents or otherwise conflate the
    standards of confidentiality between the work product and attorney-client doctrines.
    Majority Op. at 19 n.9. To the contrary, it is the sin qua non of the waiver test that the
    Majority announces today. It should be self-evident that a test measuring whether
    information was “disclosed in a manner which significantly increases the likelihood that
    an adversary or potential adversary will obtain it” requires a principal (if not exclusive)
    focus on the manner of disclosure – namely, a careful analysis of the manner in which
    the work product was disclosed to third parties, including what precautions (if any) were
    taken to safeguard against the possibility that the information could fall into the hands of
    an adversary.
    Also, I cannot agree with the generality of the Majority’s contention that courts in other
    jurisdictions have held that “depending upon the facts of a given case,” disclosing parties
    may have a reasonable basis to trust that the receiving party will not disseminate the
    material to others (even without instructions or a confidentiality agreement). 
    Id. In the
    only case cited by the Majority, United States v. Deloitte LLP, 
    610 F.3d 129
    (D.C. Cir.
    2010), the federal court of appeals there identified only one such “given case,” specifically
    a circumstance in which the disclosing party and the recipient party have “common
    litigation interests.” 
    Id. at 141.
    According to the D.C. circuit court, “when common
    litigation interests are present, ‘the transferee is not at all likely to disclose the work
    product material to the adversary.’” 
    Id. (quoting United
    States v. AT & T, 
    642 F.2d 1285
    ,
    1299 (D.C. Cir. 1980)). That court has defined “common litigation interests” to include
    those situations in which “transferor and transferee anticipate litigation against a common
    adversary on the same issue or issues.” AT & 
    T, 642 F.2d at 1300
    . No such situation
    would appear to be presented here, unless subsequent fact-finding discloses that Jarrard
    [J-80-2018] [MO: Mundy, J.] - 7
    disseminated the work product information will thus be an important, if not dispositive,
    consideration in deciding whether a finding of waiver is in order.
    Justices Todd and Dougherty join this concurring opinion.
    expected to be BouSamra’s adversary in any future litigation related to the dispute
    between BouSamra and Excela.
    [J-80-2018] [MO: Mundy, J.] - 8